A Prospective, Randomized Comparison of Promus Everolimus-Eluting and TAXUS Liberte Paclitaxel-Eluting Stent Systems in Patients with Coronary Artery Disease Eligible for Percutaneous Coronary Intervention: The PROMISE Study
We aimed comparing two-year clinical outcomes of the Everolimus-Eluting Promus and Paclitaxel-Eluting TAXUS Liberte stents used in routine clinical practice. Patients with objective evidence of ischemia and coronary artery disease eligible for PCI were prospectively randomized to everolimus-eluting...
Saved in:
| Published in | Journal of Korean medical science Vol. 28; no. 11; pp. 1609 - 1614 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Korea (South)
The Korean Academy of Medical Sciences
01.11.2013
대한의학회 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1011-8934 1598-6357 1598-6357 |
| DOI | 10.3346/jkms.2013.28.11.1609 |
Cover
| Abstract | We aimed comparing two-year clinical outcomes of the Everolimus-Eluting Promus and Paclitaxel-Eluting TAXUS Liberte stents used in routine clinical practice. Patients with objective evidence of ischemia and coronary artery disease eligible for PCI were prospectively randomized to everolimus-eluting stent (EES) or paclitaxel-eluting stent (PES) groups. The primary end-point was ischemia-driven target vessel revascularization (TVR) at 2 yr after intervention, and the secondary end-point was a major adverse cardiac event (MACE), such as death, myocardial infarction (MI), target lesion revascularization (TLR), TVR or stent thrombosis. A total of 850 patients with 1,039 lesions was randomized to the EES (n=425) and PES (n=425) groups. Ischemic-driven TVR at 2 yr was 3.8% in the PES and 1.2% in the EES group (P for non-inferiority=0.021). MACE rates were significantly different; 5.6% in PES and 2.5% in EES (P = 0.027). Rates of MI (0.8% in PES vs 0.2% in EES, P = 0.308), all deaths (1.5% in PES vs 1.2% in EES, P = 0.739) and stent thrombosis (0.3% in PES vs 0.7% in EES, P = 0.325) were similar. The clinical outcomes of EES are superior to PES, mainly due to a reduction in the rate of ischemia-driven TVR. |
|---|---|
| AbstractList | We aimed comparing two-year clinical outcomes of the Everolimus-Eluting Promus and Paclitaxel-Eluting TAXUS Liberte stents used in routine clinical practice. Patients with objective evidence of ischemia and coronary artery disease eligible for PCI were prospectively randomized to everolimus-eluting stent (EES) or paclitaxel-eluting stent (PES) groups. The primary end-point was ischemia-driven target vessel revascularization (TVR) at 2 yr after intervention, and the secondary end-point was a major adverse cardiac event (MACE), such as death, myocardial infarction (MI), target lesion revascularization (TLR), TVR or stent thrombosis. A total of 850 patients with 1,039 lesions was randomized to the EES (n=425) and PES (n=425) groups. Ischemic-driven TVR at 2 yr was 3.8% in the PES and 1.2% in the EES group (
P
for non-inferiority=0.021). MACE rates were significantly different; 5.6% in PES and 2.5% in EES (
P
= 0.027). Rates of MI (0.8% in PES vs 0.2% in EES,
P
= 0.308), all deaths (1.5% in PES vs 1.2% in EES,
P
= 0.739) and stent thrombosis (0.3% in PES vs 0.7% in EES,
P
= 0.325) were similar. The clinical outcomes of EES are superior to PES, mainly due to a reduction in the rate of ischemia-driven TVR. We aimed comparing two-year clinical outcomes of the Everolimus-Eluting Promus and Paclitaxel-Eluting TAXUS Liberte stents used in routine clinical practice. Patients with objective evidence of ischemia and coronary artery disease eligible for PCI were prospectively randomized to everolimus-eluting stent (EES) or paclitaxel-eluting stent (PES) groups. The primary end-point was ischemia-driven target vessel revascularization (TVR) at 2 yr after intervention, and the secondary end-point was a major adverse cardiac event (MACE), such as death, myocardial infarction (MI), target lesion revascularization (TLR), TVR or stent thrombosis. A total of 850 patients with 1,039 lesions was randomized to the EES (n=425) and PES (n=425) groups. Ischemic-driven TVR at 2 yr was 3.8% in the PES and 1.2% in the EES group (P for non-inferiority=0.021). MACE rates were significantly different; 5.6% in PES and 2.5% in EES (P = 0.027). Rates of MI (0.8% in PES vs 0.2% in EES, P = 0.308), all deaths (1.5% in PES vs 1.2% in EES, P = 0.739) and stent thrombosis (0.3% in PES vs 0.7% in EES, P = 0.325) were similar. The clinical outcomes of EES are superior to PES, mainly due to a reduction in the rate of ischemia-driven TVR. We aimed comparing two-year clinical outcomes of the Everolimus-Eluting Promus and Paclitaxel-Eluting TAXUS Liberte stents used in routine clinical practice. Patients with objective evidence of ischemia and coronary artery disease eligible for PCI were prospectively randomized to everolimus-eluting stent (EES) or paclitaxel-eluting stent (PES) groups. The primary end-point was ischemia-driven target vessel revascularization (TVR) at 2 yr after intervention, and the secondary end-point was a major adverse cardiac event (MACE), such as death, myocardial infarction (MI), target lesion revascularization (TLR), TVR or stent thrombosis. A total of 850 patients with 1,039 lesions was randomized to the EES (n=425) and PES (n=425) groups. Ischemic-driven TVR at 2 yr was 3.8% in the PES and 1.2% in the EES group (P for non-inferiority=0.021). MACE rates were significantly different; 5.6% in PES and 2.5% in EES (P=0.027). Rates of MI (0.8% in PES vs 0.2% in EES, P=0.308), all deaths (1.5% in PES vs 1.2% in EES, P=0.739) and stent thrombosis (0.3% in PES vs 0.7% in EES, P=0.325) were similar. The clinical outcomes of EES are superior to PES, mainly due to a reduction in the rate of ischemia-driven TVR. KCI Citation Count: 2 We aimed comparing two-year clinical outcomes of the Everolimus-Eluting Promus and Paclitaxel-Eluting TAXUS Liberte stents used in routine clinical practice. Patients with objective evidence of ischemia and coronary artery disease eligible for PCI were prospectively randomized to everolimus-eluting stent (EES) or paclitaxel-eluting stent (PES) groups. The primary end-point was ischemia-driven target vessel revascularization (TVR) at 2 yr after intervention, and the secondary end-point was a major adverse cardiac event (MACE), such as death, myocardial infarction (MI), target lesion revascularization (TLR), TVR or stent thrombosis. A total of 850 patients with 1,039 lesions was randomized to the EES (n=425) and PES (n=425) groups. Ischemic-driven TVR at 2 yr was 3.8% in the PES and 1.2% in the EES group (P for non-inferiority=0.021). MACE rates were significantly different; 5.6% in PES and 2.5% in EES (P = 0.027). Rates of MI (0.8% in PES vs 0.2% in EES, P = 0.308), all deaths (1.5% in PES vs 1.2% in EES, P = 0.739) and stent thrombosis (0.3% in PES vs 0.7% in EES, P = 0.325) were similar. The clinical outcomes of EES are superior to PES, mainly due to a reduction in the rate of ischemia-driven TVR.We aimed comparing two-year clinical outcomes of the Everolimus-Eluting Promus and Paclitaxel-Eluting TAXUS Liberte stents used in routine clinical practice. Patients with objective evidence of ischemia and coronary artery disease eligible for PCI were prospectively randomized to everolimus-eluting stent (EES) or paclitaxel-eluting stent (PES) groups. The primary end-point was ischemia-driven target vessel revascularization (TVR) at 2 yr after intervention, and the secondary end-point was a major adverse cardiac event (MACE), such as death, myocardial infarction (MI), target lesion revascularization (TLR), TVR or stent thrombosis. A total of 850 patients with 1,039 lesions was randomized to the EES (n=425) and PES (n=425) groups. Ischemic-driven TVR at 2 yr was 3.8% in the PES and 1.2% in the EES group (P for non-inferiority=0.021). MACE rates were significantly different; 5.6% in PES and 2.5% in EES (P = 0.027). Rates of MI (0.8% in PES vs 0.2% in EES, P = 0.308), all deaths (1.5% in PES vs 1.2% in EES, P = 0.739) and stent thrombosis (0.3% in PES vs 0.7% in EES, P = 0.325) were similar. The clinical outcomes of EES are superior to PES, mainly due to a reduction in the rate of ischemia-driven TVR. |
| Author | Kim, Tae-Ik Jung, Kyung-Tae Lee, Hyun-Wook Bae, Jang-Ho Jo, Jung-Hwan Park, Jong-Seon Kim, Won Hwang, Jin-Yong Lee, Jae-Hwan Cho, Jang-Hyun Kim, Ki-Sik Son, Jang-Won Cho, Myung-Chan Lee, Seung-Wook Jeong, Myung-Ho Kim, Ung Lee, Chan-Hee Park, Heon-Sik Choi, Yoon-Jung Kim, Moo-Hyun Shin, Dong-Gu Kim, Young-Jo Kang, Tae-Soo Kim, Doo-Il Lee, Sang-Hee Hur, Seung-Ho Jung, Kyung-Ho |
| AuthorAffiliation | 3 Division of Cardiology, Chungbuk National University Hospital, Cheongju, Korea 1 Division of Cardiology, Yeungnam University Medical Center, Daegu, Korea 9 Division of Cardiology, Gwangju Christian Hospital, Gwangju, Korea 11 Division of Cardiology, Kwangju Veterans Hospital, Gwangju, Korea 5 Division of Cardiology, Chungnam National University Hospital, Daejeon, Korea 2 Division of Cardiology, Chonnam National University, Gwangju, Korea 4 Division of Cardiology, Kunyang University Hospital, Daejeon, Korea 7 Division of Cardiology, Eulji University Hospital, Daejeon, Korea 12 Division of Cardiology, Keimyung Univerisity Dongsan Hospital, Daegu, Korea 16 Division of Cardiology, Kyungsang National University Hospital, Jinju, Korea 13 Division of Cardiology, Daegu Catholic University Hospital, Daegu, Korea 18 Division of Cardiology, Maryknoll Medical Center, Busan, Korea 8 Division of Cardiology, Wonkwang University Hospital, Iksan, Korea 15 Division of Cardiology, Donga University Hospital, Busan, |
| AuthorAffiliation_xml | – name: 1 Division of Cardiology, Yeungnam University Medical Center, Daegu, Korea – name: 9 Division of Cardiology, Gwangju Christian Hospital, Gwangju, Korea – name: 16 Division of Cardiology, Kyungsang National University Hospital, Jinju, Korea – name: 3 Division of Cardiology, Chungbuk National University Hospital, Cheongju, Korea – name: 10 Division of Cardiology, St. Carollo Hospital, Sooncheon, Korea – name: 8 Division of Cardiology, Wonkwang University Hospital, Iksan, Korea – name: 15 Division of Cardiology, Donga University Hospital, Busan, Korea – name: 17 Division of Cardiology, Inje University Haeundae Paik Hospital, Busan, Korea – name: 6 Division of Cardiology, Dankuk Unversity Hospital, Cheonan, Korea – name: 12 Division of Cardiology, Keimyung Univerisity Dongsan Hospital, Daegu, Korea – name: 4 Division of Cardiology, Kunyang University Hospital, Daejeon, Korea – name: 18 Division of Cardiology, Maryknoll Medical Center, Busan, Korea – name: 2 Division of Cardiology, Chonnam National University, Gwangju, Korea – name: 5 Division of Cardiology, Chungnam National University Hospital, Daejeon, Korea – name: 13 Division of Cardiology, Daegu Catholic University Hospital, Daegu, Korea – name: 11 Division of Cardiology, Kwangju Veterans Hospital, Gwangju, Korea – name: 7 Division of Cardiology, Eulji University Hospital, Daejeon, Korea – name: 14 Division of Cardiology, Kyungpook National University Hospital, Daegu, Korea |
| Author_xml | – sequence: 1 givenname: Ung surname: Kim fullname: Kim, Ung organization: Division of Cardiology, Yeungnam University Medical Center, Daegu, Korea – sequence: 2 givenname: Chan-Hee surname: Lee fullname: Lee, Chan-Hee organization: Division of Cardiology, Yeungnam University Medical Center, Daegu, Korea – sequence: 3 givenname: Jung-Hwan surname: Jo fullname: Jo, Jung-Hwan organization: Division of Cardiology, Yeungnam University Medical Center, Daegu, Korea – sequence: 4 givenname: Hyun-Wook surname: Lee fullname: Lee, Hyun-Wook organization: Division of Cardiology, Yeungnam University Medical Center, Daegu, Korea – sequence: 5 givenname: Yoon-Jung surname: Choi fullname: Choi, Yoon-Jung organization: Division of Cardiology, Yeungnam University Medical Center, Daegu, Korea – sequence: 6 givenname: Jang-Won surname: Son fullname: Son, Jang-Won organization: Division of Cardiology, Yeungnam University Medical Center, Daegu, Korea – sequence: 7 givenname: Sang-Hee surname: Lee fullname: Lee, Sang-Hee organization: Division of Cardiology, Yeungnam University Medical Center, Daegu, Korea – sequence: 8 givenname: Jong-Seon surname: Park fullname: Park, Jong-Seon organization: Division of Cardiology, Yeungnam University Medical Center, Daegu, Korea – sequence: 9 givenname: Dong-Gu surname: Shin fullname: Shin, Dong-Gu organization: Division of Cardiology, Yeungnam University Medical Center, Daegu, Korea – sequence: 10 givenname: Young-Jo surname: Kim fullname: Kim, Young-Jo organization: Division of Cardiology, Yeungnam University Medical Center, Daegu, Korea – sequence: 11 givenname: Myung-Ho orcidid: 0000-0003-4173-1494 surname: Jeong fullname: Jeong, Myung-Ho organization: Division of Cardiology, Chonnam National University, Gwangju, Korea – sequence: 12 givenname: Myung-Chan surname: Cho fullname: Cho, Myung-Chan organization: Division of Cardiology, Chungbuk National University Hospital, Cheongju, Korea – sequence: 13 givenname: Jang-Ho surname: Bae fullname: Bae, Jang-Ho organization: Division of Cardiology, Kunyang University Hospital, Daejeon, Korea – sequence: 14 givenname: Jae-Hwan surname: Lee fullname: Lee, Jae-Hwan organization: Division of Cardiology, Chungnam National University Hospital, Daejeon, Korea – sequence: 15 givenname: Tae-Soo surname: Kang fullname: Kang, Tae-Soo organization: Division of Cardiology, Dankuk Unversity Hospital, Cheonan, Korea – sequence: 16 givenname: Kyung-Tae surname: Jung fullname: Jung, Kyung-Tae organization: Division of Cardiology, Eulji University Hospital, Daejeon, Korea – sequence: 17 givenname: Kyung-Ho surname: Jung fullname: Jung, Kyung-Ho organization: Division of Cardiology, Wonkwang University Hospital, Iksan, Korea – sequence: 18 givenname: Seung-Wook surname: Lee fullname: Lee, Seung-Wook organization: Division of Cardiology, Gwangju Christian Hospital, Gwangju, Korea – sequence: 19 givenname: Jang-Hyun surname: Cho fullname: Cho, Jang-Hyun organization: Division of Cardiology, St. Carollo Hospital, Sooncheon, Korea – sequence: 20 givenname: Won surname: Kim fullname: Kim, Won organization: Division of Cardiology, Kwangju Veterans Hospital, Gwangju, Korea – sequence: 21 givenname: Seung-Ho orcidid: 0000-0002-3895-1915 surname: Hur fullname: Hur, Seung-Ho organization: Division of Cardiology, Keimyung Univerisity Dongsan Hospital, Daegu, Korea – sequence: 22 givenname: Ki-Sik surname: Kim fullname: Kim, Ki-Sik organization: Division of Cardiology, Daegu Catholic University Hospital, Daegu, Korea – sequence: 23 givenname: Heon-Sik surname: Park fullname: Park, Heon-Sik organization: Division of Cardiology, Kyungpook National University Hospital, Daegu, Korea – sequence: 24 givenname: Moo-Hyun surname: Kim fullname: Kim, Moo-Hyun organization: Division of Cardiology, Donga University Hospital, Busan, Korea – sequence: 25 givenname: Jin-Yong surname: Hwang fullname: Hwang, Jin-Yong organization: Division of Cardiology, Kyungsang National University Hospital, Jinju, Korea – sequence: 26 givenname: Doo-Il surname: Kim fullname: Kim, Doo-Il organization: Division of Cardiology, Inje University Haeundae Paik Hospital, Busan, Korea – sequence: 27 givenname: Tae-Ik surname: Kim fullname: Kim, Tae-Ik organization: Division of Cardiology, Maryknoll Medical Center, Busan, Korea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24265523$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001819009$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNp9Us2O0zAQjtAi9gfeACEfOZASx06a7AGpKl2oVLRV25W4WU4yab1N7GI7ZcvT8ihMtmwFHDhYM3K-n8n4uwzOtNEQBK9pNGCMp-_vt60bxBFlgzgbUDqgaZQ_Cy5okmdhypLhGfYRpWGWM34eXDp3H0VxksTsRXAe8zjt24vg54jMrXE7KL3awzuykLoyrfoBFRmbdietckYTU_eotnNksgdrGoVtOGk6r_SaIIOsRl_vlmSmCrAeyFyWjfLyAZoTaOlBe7I8OA-tI0ojxiu8cuS78hv0skZLeyAj5GP5qBxIB2TSqLUqGiC1sWQOtuy81GBwkBNjqpGxRyll9DVZbdB-cftlupygZ1cdXgbPa9k4ePW7XgV3N5PV-HM4u_00HY9mYck59SGDqmZxFDM2lMOi4qxKMuBpyZmM6wIAcL08ZkWV5bxIayYLWtKcY1cXeHJ2Fbw96mpbi22phJHqsa6N2FoxWqymIhkyyhlCPxyhu65ooSpxdisbsbOqxR96JP79RasNyuwFy1iS4Iwnr5013zpwXrTKldA0x90IylPKWJYk_Vhv_vQ6mTwlAAHXR0CJMXAWalHi0_XLRGvVCBqJPm6ij5vo4ybiTFAq-rghmf9DftL_L-0XN1ngEA |
| CitedBy_id | crossref_primary_10_1007_s12181_017_0202_9 crossref_primary_10_3346_jkms_2024_39_e234 crossref_primary_10_1016_j_rec_2014_07_011 crossref_primary_10_4244_EIJ_D_17_00646 crossref_primary_10_1016_j_recesp_2014_07_012 crossref_primary_10_1161_CIRCULATIONAHA_115_016779 |
| Cites_doi | 10.1016/j.amjcard.2012.05.050 10.1056/NEJMoa0910496 10.1002/ccd.23200 10.1161/CIRCULATIONAHA.106.685313 10.1056/NEJMoa032441 10.1016/S0140-6736(09)62127-9 10.1161/01.CIR.0000150331.14687.4B 10.1016/j.jcin.2012.06.020 10.1016/j.jacc.2007.01.069 10.1001/jama.299.16.1903 |
| ContentType | Journal Article |
| Copyright | 2013 The Korean Academy of Medical Sciences. 2013 |
| Copyright_xml | – notice: 2013 The Korean Academy of Medical Sciences. 2013 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ACYCR |
| DOI | 10.3346/jkms.2013.28.11.1609 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1598-6357 |
| EndPage | 1614 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_573143 PMC3835502 24265523 10_3346_jkms_2013_28_11_1609 |
| Genre | Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Boston Scientific – fundername: Abbott |
| GroupedDBID | --- 29K 2WC 3O- 5-W 53G 5GY 8JR 8XY 9ZL AAYXX ADBBV ADRAZ AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION CS3 D-I DIK DU5 E3Z EBS EF. EJD F5P FRP GROUPED_DOAJ GX1 HYE KQ8 M48 O5R O5S OK1 OVT PGMZT RNS RPM TR2 W2D XSB CGR CUY CVF ECM EIF NPM 7X8 5PM ACYCR |
| ID | FETCH-LOGICAL-c441t-3edf3202337a7bd43d58e46c43a2fbeee160423bd894b6f3ab1c1946f3fbf3f93 |
| IEDL.DBID | M48 |
| ISSN | 1011-8934 1598-6357 |
| IngestDate | Sun Mar 09 07:53:12 EDT 2025 Thu Aug 21 14:14:50 EDT 2025 Fri Jul 11 03:24:30 EDT 2025 Mon Jul 21 06:03:57 EDT 2025 Tue Jul 01 01:44:48 EDT 2025 Thu Apr 24 23:06:44 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Keywords | Everolimus-Eluting Stent Paclitaxel-Eluting Stent |
| Language | English |
| License | http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c441t-3edf3202337a7bd43d58e46c43a2fbeee160423bd894b6f3ab1c1946f3fbf3f93 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 G704-000345.2013.28.11.009 |
| ORCID | 0000-0002-3895-1915 0000-0003-4173-1494 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3346/jkms.2013.28.11.1609 |
| PMID | 24265523 |
| PQID | 1461338559 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_573143 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3835502 proquest_miscellaneous_1461338559 pubmed_primary_24265523 crossref_citationtrail_10_3346_jkms_2013_28_11_1609 crossref_primary_10_3346_jkms_2013_28_11_1609 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2013-11-01 |
| PublicationDateYYYYMMDD | 2013-11-01 |
| PublicationDate_xml | – month: 11 year: 2013 text: 2013-11-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | Journal of Korean medical science |
| PublicationTitleAlternate | J Korean Med Sci |
| PublicationYear | 2013 |
| Publisher | The Korean Academy of Medical Sciences 대한의학회 |
| Publisher_xml | – name: The Korean Academy of Medical Sciences – name: 대한의학회 |
| References | Maluenda (10.3346/jkms.2013.28.11.1609_ref11) 2012; 80 Serruys (10.3346/jkms.2013.28.11.1609_ref6) 2006; 2 Kedhi (10.3346/jkms.2013.28.11.1609_ref8) 2010; 375 Stone (10.3346/jkms.2013.28.11.1609_ref12) 2008; 299 Kedhi (10.3346/jkms.2013.28.11.1609_ref7) 2012; 5 Popma (10.3346/jkms.2013.28.11.1609_ref1) 2004; 110 Stone (10.3346/jkms.2013.28.11.1609_ref2) 2004; 350 Stone (10.3346/jkms.2013.28.11.1609_ref9) 2010; 362 Serruys (10.3346/jkms.2013.28.11.1609_ref5) 2005; 1 Waksman (10.3346/jkms.2013.28.11.1609_ref10) 2012; 110 Turco (10.3346/jkms.2013.28.11.1609_ref4) 2007; 49 Cutlip (10.3346/jkms.2013.28.11.1609_ref3) 2007; 115 19758878 - EuroIntervention. 2005 May;1(1):58-65 21735521 - Catheter Cardiovasc Interv. 2012 Jul 1;80(1):29-36 17470709 - Circulation. 2007 May 1;115(17):2344-51 18430909 - JAMA. 2008 Apr 23;299(16):1903-13 15596568 - Circulation. 2004 Dec 21;110(25):3773-80 19755303 - EuroIntervention. 2006 Nov;2(3):286-94 17448368 - J Am Coll Cardiol. 2007 Apr 24;49(16):1676-83 20060578 - Lancet. 2010 Jan 16;375(9710):201-9 23174638 - JACC Cardiovasc Interv. 2012 Nov;5(11):1141-9 14724301 - N Engl J Med. 2004 Jan 15;350(3):221-31 20445180 - N Engl J Med. 2010 May 6;362(18):1663-74 22762711 - Am J Cardiol. 2012 Oct 15;110(8):1119-24 |
| References_xml | – volume: 110 start-page: 1119 year: 2012 ident: 10.3346/jkms.2013.28.11.1609_ref10 publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2012.05.050 – volume: 1 start-page: 58 year: 2005 ident: 10.3346/jkms.2013.28.11.1609_ref5 publication-title: EuroIntervention – volume: 362 start-page: 1663 year: 2010 ident: 10.3346/jkms.2013.28.11.1609_ref9 publication-title: N Engl J Med doi: 10.1056/NEJMoa0910496 – volume: 80 start-page: 29 year: 2012 ident: 10.3346/jkms.2013.28.11.1609_ref11 publication-title: Catheter Cardiovasc Interv doi: 10.1002/ccd.23200 – volume: 115 start-page: 2344 year: 2007 ident: 10.3346/jkms.2013.28.11.1609_ref3 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.106.685313 – volume: 350 start-page: 221 year: 2004 ident: 10.3346/jkms.2013.28.11.1609_ref2 publication-title: N Engl J Med doi: 10.1056/NEJMoa032441 – volume: 375 start-page: 201 year: 2010 ident: 10.3346/jkms.2013.28.11.1609_ref8 publication-title: Lancet doi: 10.1016/S0140-6736(09)62127-9 – volume: 110 start-page: 3773 year: 2004 ident: 10.3346/jkms.2013.28.11.1609_ref1 publication-title: Circulation doi: 10.1161/01.CIR.0000150331.14687.4B – volume: 2 start-page: 286 year: 2006 ident: 10.3346/jkms.2013.28.11.1609_ref6 publication-title: EuroIntervention – volume: 5 start-page: 1141 year: 2012 ident: 10.3346/jkms.2013.28.11.1609_ref7 publication-title: JACC Cardiovasc Interv doi: 10.1016/j.jcin.2012.06.020 – volume: 49 start-page: 1676 year: 2007 ident: 10.3346/jkms.2013.28.11.1609_ref4 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2007.01.069 – volume: 299 start-page: 1903 year: 2008 ident: 10.3346/jkms.2013.28.11.1609_ref12 publication-title: JAMA doi: 10.1001/jama.299.16.1903 – reference: 18430909 - JAMA. 2008 Apr 23;299(16):1903-13 – reference: 17448368 - J Am Coll Cardiol. 2007 Apr 24;49(16):1676-83 – reference: 17470709 - Circulation. 2007 May 1;115(17):2344-51 – reference: 20445180 - N Engl J Med. 2010 May 6;362(18):1663-74 – reference: 14724301 - N Engl J Med. 2004 Jan 15;350(3):221-31 – reference: 21735521 - Catheter Cardiovasc Interv. 2012 Jul 1;80(1):29-36 – reference: 15596568 - Circulation. 2004 Dec 21;110(25):3773-80 – reference: 23174638 - JACC Cardiovasc Interv. 2012 Nov;5(11):1141-9 – reference: 22762711 - Am J Cardiol. 2012 Oct 15;110(8):1119-24 – reference: 19758878 - EuroIntervention. 2005 May;1(1):58-65 – reference: 19755303 - EuroIntervention. 2006 Nov;2(3):286-94 – reference: 20060578 - Lancet. 2010 Jan 16;375(9710):201-9 |
| SSID | ssj0025523 |
| Score | 2.006825 |
| Snippet | We aimed comparing two-year clinical outcomes of the Everolimus-Eluting Promus and Paclitaxel-Eluting TAXUS Liberte stents used in routine clinical practice.... |
| SourceID | nrf pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1609 |
| SubjectTerms | Antineoplastic Agents, Phytogenic - administration & dosage Antineoplastic Agents, Phytogenic - therapeutic use Coronary Artery Disease - drug therapy Coronary Artery Disease - mortality Coronary Restenosis - prevention & control Drug-Eluting Stents Everolimus Female Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - therapeutic use Male Middle Aged Original Paclitaxel - administration & dosage Paclitaxel - therapeutic use Percutaneous Coronary Intervention - methods Prospective Studies Sirolimus - administration & dosage Sirolimus - analogs & derivatives Sirolimus - therapeutic use Thrombosis Treatment Outcome 의학일반 |
| Title | A Prospective, Randomized Comparison of Promus Everolimus-Eluting and TAXUS Liberte Paclitaxel-Eluting Stent Systems in Patients with Coronary Artery Disease Eligible for Percutaneous Coronary Intervention: The PROMISE Study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/24265523 https://www.proquest.com/docview/1461338559 https://pubmed.ncbi.nlm.nih.gov/PMC3835502 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001819009 |
| Volume | 28 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Journal of Korean Medical Science, 2013, 28(11), 182, pp.1609-1614 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3battAEF2SFEpfSu9xL2YKfeyGSLu6FUoxqULc4tbEMfht0WU3FbalVpYh6df2UzqjG3FJKfTBSKBZryyd9ZzZnT3D2Bv0MBhUJBG3Pdfl0pMOj7WTcOTKMjg2XqBryfzJF_dsLj8tnMUe62q2tg9wc2toR_Wk5uXq6OrH9Qcc8O8p4hS0Qrlck_C2JY5sH_8CaMIk2Gd30De5FI5NZL-ugPzZblLuLYujp5bNZrq_fgtJBaMLo1Y7fms_L81tlPTPzMobrur0AbvfckwYNaB4yPZ0_ojdnbSr6I_ZrxFMy6LbY_kWzqM8LdbZT53CSV-WEApDVuvtBkKEe7HK8JSHBNT8ErAFXIwW8xnUKSeVhmmUkN73lV71RjPk4xW0muiQ5WhTi7hugGZ_sa-yoM3AdKMaDx-btSIIKUk6XmlAPg1TXSZbJLC6wBvpW4xvZGq-A4Q6TM-_TsazECgv8voJm5-GFydnvK30wBOkYxUXOjV1IXfhRV6cSpE6vpZuIkVkm1hrjS8DeV-c-oGMXSOi2EqsQOKZifETiKfsIC9yfcjApJYgmPnG0TIQSLciT5PIvOMlgW3sARPde1RJK4NO1ThWCsMhAoIiICgCgrJ9DJAUAWHAeN_qeyMD8g_71wgRtUwyRfrddLws1LJUGKWMleMJpKlo0wFI4ZimhZrmaVI4RlMHGOwN2LMGUH2vHR4HzNuBWm9A_e1eybNvtW64QLbtHNvP_7vlC3aPfmezFfMlO6jKrX6FnKyKhxiNjD8P6xmNYT3kfgNNXjj_ |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Prospective%2C+Randomized+Comparison+of+Promus+Everolimus-Eluting+and+TAXUS+Liberte+Paclitaxel-Eluting+Stent+Systems+in+Patients+with+Coronary+Artery+Disease+Eligible+for+Percutaneous+Coronary+Intervention%3A+The+PROMISE+Study&rft.jtitle=Journal+of+Korean+medical+science&rft.au=Kim%2C+Ung&rft.au=Lee%2C+Chan-Hee&rft.au=Jo%2C+Jung-Hwan&rft.au=Lee%2C+Hyun-Wook&rft.date=2013-11-01&rft.pub=The+Korean+Academy+of+Medical+Sciences&rft.issn=1011-8934&rft.eissn=1598-6357&rft.volume=28&rft.issue=11&rft.spage=1609&rft.epage=1614&rft_id=info:doi/10.3346%2Fjkms.2013.28.11.1609&rft_id=info%3Apmid%2F24265523&rft.externalDocID=PMC3835502 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1011-8934&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1011-8934&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1011-8934&client=summon |